PHAR

Pharming Group N.V. ADS, each representing 10 ordinary shares

16.20

USD

PHAR Earnings Reports

Positive Surprise Ratio

PHAR beat 20 of 40 last estimates.

50%

Next Report

Date of Next Report

May 07, 2026

Estimate for Q1 26 (Revenue/ EPS)

$96.56M

$0.00

Implied change from Q4 25 (Revenue/ EPS)

-9.36%

Implied change from Q1 25 (Revenue/ EPS)

+22.09%

-100.00%

Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue

On Mar 12, 2026, PHAR reported earnings of 0.00 USD per share (EPS) for Q4 25, missing the estimate of 0.00 USD, resulting in a -6.98% surprise. Revenue reached 106.53 million, compared to an expected 108.35 million, with a -1.67% difference. The market reacted with a +4.58% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 96.56 million USD, implying an increase of 0.00% EPS, and decrease of -9.36% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.00, missing estimates by -6.98%, and revenue of $106.53M, -1.67% below expectations.

How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q4 2025 earnings?

The stock price moved up 4.58%, changed from $17.89 before the earnings release to $18.71 the day after.

When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?

The next earning report is scheduled for May 07, 2026.

What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?

Based on 4 analysts, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of -- and revenue of $96.56M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.